Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma

Journal of Hepatology

Volumn 54, Issue 5, 2011, Pages 1073-1078

  Marijon, Hélène ^a   Dokmak, Safi ^a   Paradis, Valérie ^a   Zappa, Magaly ^a   Bieche, Ivan ^a   Bouattour, Mohamed ^a   Raymond, Eric ^a   Faivre, Sandrine ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Acquired resistance; Advanced HCC; Anti angiogenics; Epithelial to mesenchymal transition; Sunitinib

Indexed keywords

ALPHA FETOPROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY KI 67; SUNITINIB; UVOMORULIN; VIMENTIN;

ABDOMINAL PAIN; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD LEVEL; CANCER CELL; CANCER RESISTANCE; CANCER SURGERY; CASE REPORT; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); DRUG EXPOSURE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER RESECTION; MALE; MYASTHENIA; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALVAGE THERAPY; SEROLOGY; SKIN TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VOLUME;

AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INDOLES; LIVER NEOPLASMS; MALE; PYRROLES;

EID: 79954888961     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.11.011     Document Type: Article

References (21)

1. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
2. S. Faivre, E. Raymond, E. Boucher, J. Douillard, H.Y. Lim, and J.S. Kim Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study Lancet Oncol 10 2009 794 800
3. R.S. Benjamin, H. Choi, H.A. Macapinlac, M.A. Burgess, S.R. Patel, and L.L. Chen We should desist using RECIST, at least in GIST J Clin Oncol 25 2007 1760 1764 (Pubitemid 46797958)
4. A. Ghoul, M. Serova, L. Astorgues-Xerri, I. Bieche, G. Bousquet, and M. Varna Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells Cancer Res 69 2009 4260 4269
5. C.Y. Kwon, K.R. Kim, H.N. Choi, M.J. Chung, S.J. Noh, and D.G. Kim The role of serum response factor in hepatocellular carcinoma: implications for disease progression Int J Oncol 37 2010 837 844
6. M.Y. Park, K.R. Kim, H.S. Park, B.-H. Park, H.N. Choi, and K.Y. Jang Expression of the serum response factor in hepatocellular carcinoma: implications for epithelial-mesenchymal transition Int J Incol 31 2007 1309 1315
7. M. Sabbah, S. Emami, G. Redeuilh, S. Julien, G. Prévost, and A. Zimber Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers Drug Resist Updat 11 2008 123 151
8. M.I. Kokkinos, R. Wafai, M.K. Wong, D.F. Newgreen, E.W. Thompson, and M. Waltham Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and in vivo Cells Tissues Organs 185 2007 191 203 (Pubitemid 46957486)
9. A.D. Yang, F. Fan, E.R. Camp, G. van Buren, W. Liu, and R. Somcio Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines Clin Cancer Res 12 2006 4147 4153
10. H. Kajiyama, K. Shibata, M. Terauchi, M. Yamashita, K. Ino, and A. Nawa Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells Int J Oncol 31 2007 277 283
11. R.L. Yauch, T. Januario, D.A. Eberhard, G. Cavet, W. Zhu, and L. Fu Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients Clin Cancer Res 11 2005 8686 8698 (Pubitemid 43005918)
12. S. Thuault, U. Valcourt, M. Petersen, G. Manfioletti, C.H. Heldin, and A. Moustakas Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition J Cell Biol 174 2006 175 183 (Pubitemid 44079853)
13. S. Watanabe, Y. Ueda, S.-i. Akaboshi, Y. Hino, Y. Sekita, and M. Nakaoet HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells Am J Pathol 174 2009 854 868
14. H.J. Hammers, H.M. Verheul, B. Salumbides, R. Sharma, M. Rudek, and J. Jaspers Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study Mol Cancer Ther 9 2010 1525 1535
15. J.S. Ko, P. Rayman, J. Ireland, S. Swaidani, G. Li, and K.D. Bunting Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained Cancer Res 70 2010 3526 3536
16. R. Schietke, C. Warnecke, I. Wacker, J. Schödel, D.R. Mole, and V. Campean The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1 J Biol Chem 285 2010 6658 6669
17. M.R. Mancuso, R. Davis, S.M. Norberg, S. O'Brien, B. Sennino, and T. Nakahara Rapid vascular regrowth in tumors after reversal of VEGF inhibition J Clin Invest 116 2006 2610 2621 (Pubitemid 44511625)
18. B. Sennino, F. Kuhnert, S.P. Tabruyn, M.R. Mancuso, D.D. Hu-Lowe, and C.J. Kuo Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors Cancer Res 69 2009 4527 4536
19. R.S. Bhatt, X. Wang, L. Zhang, M.P. Collins, S. Signoretti, and D.C. Alsop Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling Mol Cancer Ther 9 2010 2793 2802
20. D. Huang, Y. Ding, M. Zhou, B.I. Rini, D. Petillo, and C.-N. Qian Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma Cancer Res 70 2010 1063 1071
21. F. Shojaei, J.H. Lee, B.H. Simmons, A. Wong, C.O. Esparza, and P.A. Plumlee HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors Cancer Res 70 2010 10090 10100